Technology
Coeptis Therapeutics Holdings, Inc.(COEP)
Live Price
Offline$16.40
+0.00% today
Window Change
+132.62%
Window
Jun 23, 2025 โ Apr 24, 2026
- Market Cap
- $57.63M
- Revenue Growth
- 0.0%
- EPS Growth
- +50.3%
- Dividend Yield
- 0.0%
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 212 bars ยท Jun 23, 2025 โ Apr 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Coeptis Therapeutics Holdings, Inc. (COEP) is a Technology stock with a market cap of $57.63M and listed on NASDAQ. The stock last traded around $16.40 and up 132.6% across the available one-year price window (Jun 23, 2025 โ Apr 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +50.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +50.3%, free cash flow -29.4% with operating margin -956.9% and ROIC -55.7%. Valuation already assumes a fairly strong business story at price/sales 42.3. Stock Foundry combines COEP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Technology peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +11.9% peer median
Operating Margin
Below sector median
-956.9% vs +22.0% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 3, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +50.3%, while operating margin sits near -956.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +9.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 19, 2026 | +85.0% | +0.0% | -3.4% | +29.6% |
2025 Nov 13, 2025 | โ | +2.9% | +15.3% | +6.9% |
2025 Aug 14, 2025 | โ | +21.7% | +17.0% | +13.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
COEP
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
COEP Max Drawdown
-44.68%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for COEP and SPY.
Company Overview
Coeptis Therapeutics Holdings, Inc.
NASDAQ
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company that concentrates on developing cell therapy technologies for the treatment of cancer. At the forefront of innovative medical solutions, Coeptis focuses on enhancing the effectiveness of existing oncology therapies, aiming to improve outcomes for patients battling various forms of cancer. One of the defining features of Coeptis Therapeutics is its specialized approach to advancing cell therapy capabilities, which plays a critical role in the burgeoning biopharmaceutical sector. This approach not only supports the development of novel treatment methodologies but also helps to set new benchmarks in the industry. By engaging in strategic collaborations and partnerships, Coeptis Therapeutics is able to leverage cutting-edge scientific research and integrate these advances into practical, clinical applications. With its core capabilities focused on the biotechnology space, Coeptis Therapeutics occupies a pivotal position in the driving wave of therapeutic innovations within the pharmaceutical industry, addressing unmet medical needs and contributing significantly to global healthcare advancements.
- Leadership
- Mr. David Halabu
- Employees
- 4
- Street Address
- 500 Andrews Ave, Suite 700
- Mailing
- Fort Lauderdale, FL, 33301
- Region
- Fort Lauderdale, FL, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 42.3
- Price/Book
- 4.0
Growth
- Revenue
- 0.0%
- EPS
- +50.3%
- Free Cash Flow
- -29.4%
Profitability
- Gross Margin
- -207.8%
- Operating Margin
- -956.9%
- Net Margin
- -611.1%
- ROE
- -78.8%
- ROIC
- -55.7%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 4.16
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.